[go: up one dir, main page]

FR24C1015I1 - Derives 2,2-difluoropropionamide de bardoxolone methyle, leurs formes polymorphes et leurs procedes d'utilisation - Google Patents

Derives 2,2-difluoropropionamide de bardoxolone methyle, leurs formes polymorphes et leurs procedes d'utilisation

Info

Publication number
FR24C1015I1
FR24C1015I1 FR24C1015C FR24C1015C FR24C1015I1 FR 24C1015 I1 FR24C1015 I1 FR 24C1015I1 FR 24C1015 C FR24C1015 C FR 24C1015C FR 24C1015 C FR24C1015 C FR 24C1015C FR 24C1015 I1 FR24C1015 I1 FR 24C1015I1
Authority
FR
France
Prior art keywords
methods
polymorphic forms
bardoxolone methyl
difluoropropionamide
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR24C1015C
Other languages
English (en)
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Reata Pharmaceuticals Holdings LLC
Original Assignee
Reata Pharmaceuticals Holdings LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reata Pharmaceuticals Holdings LLC filed Critical Reata Pharmaceuticals Holdings LLC
Publication of FR24C1015I1 publication Critical patent/FR24C1015I1/fr
Active legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J63/00Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/008Expansion of ring D by one atom, e.g. D homo steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/275Nitriles; Isonitriles
    • A61K31/277Nitriles; Isonitriles having a ring, e.g. verapamil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/16Emollients or protectives, e.g. against radiation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/06Free radical scavengers or antioxidants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00Carboxylic acid nitriles
    • C07C255/45Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C255/47Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of rings being part of condensed ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
FR24C1015C 2012-04-27 2024-04-17 Derives 2,2-difluoropropionamide de bardoxolone methyle, leurs formes polymorphes et leurs procedes d'utilisation Active FR24C1015I1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261687669P 2012-04-27 2012-04-27
US201361775288P 2013-03-08 2013-03-08
US201361780444P 2013-03-13 2013-03-13
PCT/US2013/038064 WO2013163344A1 (en) 2012-04-27 2013-04-24 2.2-difluoropropionamide derivatives of bardoxolone methyl, polymorphic forms and methods of use thereof

Publications (1)

Publication Number Publication Date
FR24C1015I1 true FR24C1015I1 (fr) 2024-06-28

Family

ID=49483867

Family Applications (1)

Application Number Title Priority Date Filing Date
FR24C1015C Active FR24C1015I1 (fr) 2012-04-27 2024-04-17 Derives 2,2-difluoropropionamide de bardoxolone methyle, leurs formes polymorphes et leurs procedes d'utilisation

Country Status (40)

Country Link
US (5) US8993640B2 (nl)
EP (2) EP2841445B1 (nl)
JP (2) JP6410710B2 (nl)
KR (1) KR102101774B1 (nl)
CN (1) CN104395332B (nl)
AR (1) AR092823A1 (nl)
AU (1) AU2013251602B2 (nl)
BR (1) BR112014026640B1 (nl)
CA (1) CA2869783C (nl)
CL (1) CL2014002886A1 (nl)
CO (1) CO7170182A2 (nl)
CY (3) CY1119333T1 (nl)
DK (2) DK3444261T3 (nl)
DO (1) DOP2014000236A (nl)
EA (1) EA030468B1 (nl)
ES (2) ES2634315T3 (nl)
FI (1) FIC20240012I1 (nl)
FR (1) FR24C1015I1 (nl)
HK (2) HK1207085A1 (nl)
HR (1) HRP20171275T1 (nl)
HU (3) HUE035673T2 (nl)
IL (1) IL235275B (nl)
LT (2) LT3444261T (nl)
ME (1) ME02926B (nl)
MX (1) MX357060B (nl)
MY (1) MY172750A (nl)
NL (1) NL301276I2 (nl)
NZ (1) NZ630222A (nl)
PE (1) PE20150160A1 (nl)
PL (2) PL2841445T3 (nl)
PT (2) PT2841445T (nl)
RS (2) RS56154B1 (nl)
SG (1) SG11201406868XA (nl)
SI (2) SI2841445T1 (nl)
SM (2) SMT201700396T1 (nl)
TW (2) TW201348245A (nl)
UA (1) UA116209C2 (nl)
UY (1) UY34764A (nl)
WO (1) WO2013163344A1 (nl)
ZA (1) ZA201407326B (nl)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2252283T1 (sl) 2008-01-11 2019-02-28 Reata Pharmaceuticals, Inc. Sintetični triterpenoidi in postopki uporabe pri zdravljenju bolezni
JP5564490B2 (ja) 2008-04-18 2014-07-30 リアタ ファーマシューティカルズ インコーポレイテッド 抗炎症性ファルマコアを含む化合物および使用法
CN102083442B (zh) 2008-04-18 2014-08-13 里亚塔医药公司 抗氧化剂炎症调节剂:在c-17具有氨基和其它修饰的齐墩果酸衍生物
SMT201800069T1 (it) 2010-12-17 2018-03-08 Reata Pharmaceuticals Inc Pirazolil- e pirimidinilenoni triciclici quali modulatori d'infiammazione antiossidanti
US20130158077A1 (en) 2011-12-19 2013-06-20 Ares Trading S.A. Pharmaceutical compositions
SI2841445T1 (sl) 2012-04-27 2017-12-29 Reata Pharmaceuticals, Inc. 2,2-difluoropropionamidni derivati bardoksolon metila, njihove polimorfne oblike in postopki za njihovo uporabo
US9556222B2 (en) 2012-06-15 2017-01-31 Reata Pharmaceuticals, Inc. A-ring epoxidized triterpenoid-based anti-inflammation modulators and methods of use thereof
AU2013312106B2 (en) 2012-09-10 2018-03-08 Reata Pharmaceuticals, Inc. C17-alkanediyl and alkenediyl derivatives of oleanolic acid and methods of use thereof
US9512094B2 (en) 2012-09-10 2016-12-06 Reata Pharmaceuticals, Inc. C17-heteroaryl derivatives of oleanolic acid and methods of use thereof
TWI649330B (zh) 2013-04-24 2019-02-01 艾伯維有限公司 甲基巴多索龍之2,2-二氟丙醯胺衍生物、其多晶形及其使用方法
WO2016070063A1 (en) 2014-10-31 2016-05-06 The Regents Of The University Of California Compositions and methods for treating hiv-associated cognitive dysfunction
KR102686868B1 (ko) 2015-02-12 2024-07-19 리아타 파마슈티컬즈, 아이엔씨. 항산화 염증 조절제로서의 이미다졸릴 트리사이클릭 에논
US11584775B2 (en) 2015-09-23 2023-02-21 Reata Pharmaceuticals, Inc. C4-modified oleanolic acid derivatives for inhibition of IL-17 and other uses
US10953020B2 (en) 2016-11-08 2021-03-23 Reata Pharmaceuticals, Inc. Methods of treating Alport syndrome using bardoxolone methyl or analogs thereof
TWI831738B (zh) 2016-12-16 2024-02-11 美商瑞塔醫藥有限責任公司 用於抑制RORγ及其他用途的嘧啶三環烯酮衍生物
BR112020023943A2 (pt) * 2018-05-24 2021-02-09 Renibus Therapeutics, Inc. métodos de tratamento de pacientes em risco de lesão renal e insuficiência renal
WO2019241796A1 (en) 2018-06-15 2019-12-19 Reata Pharmaceuticals, Inc. Pyrazole and imidazole compounds for inhibition of il-17 and rorgamma
US12060340B2 (en) 2018-06-20 2024-08-13 Reata Pharmaceuticals, Inc Cysteine-dependent inverse agonists of nuclear receptors ROR-gamma/ROR-gamma-t and methods of treating diseases or disorders therewith
EP4364804A3 (en) 2018-08-20 2024-09-04 Janssen Pharmaceutica NV Inhibitors of keap1-nrf2 protein-protein interaction
WO2020167969A1 (en) * 2019-02-15 2020-08-20 Triterpenoid Therapeutics, Inc. Methods and compositions for inhibiting the nlrp3 inflammasome and/or lon protease
JP2023504194A (ja) * 2019-12-03 2023-02-01 ベイラー カレッジ オブ メディスン インスリン耐性における使用方法のための治療化合物
MX2022008914A (es) 2020-01-24 2022-08-16 Tvardi Therapeutics Inc Compuestos terapeuticos, formulaciones y usos de los mismos.
AU2021397631A1 (en) 2020-12-11 2023-07-20 Reata Pharmaceuticals Holdings, LLC Synthetic triterpenoids for use in therapy
EP4277916A1 (en) 2021-01-18 2023-11-22 Reata Pharmaceuticals, Inc. Synthetic ursolic acid derivatives and methods of use thereof
CN113197905B (zh) * 2021-04-23 2022-04-19 浙江大学 三萜类化合物在制备神经母细胞瘤治疗药物中的应用
CN113358627B (zh) * 2021-06-23 2022-07-01 华中农业大学 一种基于拉曼检测的田间快速测定茶树品质成分的方法
CN114344308A (zh) * 2021-12-22 2022-04-15 山西医科大学第二医院 甲基巴多索隆在制备防治骨关节炎的药物中的应用
WO2023244946A1 (en) 2022-06-15 2023-12-21 Tvardi Therapeutics, Inc. Prodrugs of stat3 inhibitors
EP4349847A1 (en) 2022-09-21 2024-04-10 Sicor Società Italiana Corticosteroidi S.r.l. Process and intermediates for preparation of omaveloxolone and salts thereof
WO2025029691A1 (en) 2023-07-28 2025-02-06 Reata Pharmaceuticals Holdings, LLC Methods for producing triterpenoid derivatives

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5555153Y2 (nl) 1975-03-19 1980-12-20
NZ191586A (en) 1978-10-10 1981-10-19 Sterling Drug Inc Cyanoketones derived from glycyrrhetinic acid and pharmaceutical compositions
US4395423A (en) 1978-10-10 1983-07-26 Sterling Drug Inc. Polycyclic cyanoketones
US5064823A (en) 1988-08-24 1991-11-12 Research Triangle Institute Pentacyclic triterpenoid compounds as topoisomerase inhibitors or cell differentiation inducers
US6025395A (en) 1994-04-15 2000-02-15 Duke University Method of preventing or delaying the onset and progression of Alzheimer's disease and related disorders
US6326507B1 (en) 1998-06-19 2001-12-04 Trustees Of Dartmouth College Therapeutic compounds and methods of use
US6369101B1 (en) 1999-02-26 2002-04-09 Regents Of The University Of Minnesota Therapeutic method to treat herpes virus infection
NZ515675A (en) 1999-05-14 2004-06-25 Nereus Pharmaceuticals Inc Novel interleukin-1 and tumor necrosis factor-alpha modulators, syntheses of said modulators and methods of using said modulators
US6649654B1 (en) 1999-11-23 2003-11-18 The Regents Of The University Of California Methods for identifying and using IKK inhibitors
JP2001240573A (ja) 2000-03-01 2001-09-04 Meiji Seika Kaisha Ltd トリテルペン誘導体及び肝疾患治療剤
WO2002003996A1 (en) 2000-07-12 2002-01-17 RAJKUMAR, Sujatha Use of dammarane-type tritepenoid saporins
US6951847B2 (en) 2000-09-29 2005-10-04 Regents Of The University Of Minnesota Methods of treating fungal infections using lupeol
EP1322661A1 (en) 2000-09-29 2003-07-02 Regents Of The University Of Minnesota Triterpenes having fungicidal activity against yeast
US6689767B2 (en) 2000-09-29 2004-02-10 Regents Of The University Of Minnesota Triterpenes having antibacterial activity
US6878751B1 (en) 2000-10-19 2005-04-12 Imperial College Of Science Technology And Medicine Administration of resveratrol to treat inflammatory respiratory disorders
AU2002243246A1 (en) 2000-11-28 2002-06-24 Board Of Regents, The University Of Texas System Cddo-compounds and combination therapies thereof
US7435755B2 (en) 2000-11-28 2008-10-14 The Trustees Of Dartmouth College CDDO-compounds and combination therapies thereof
AU2002308701A1 (en) 2001-05-14 2002-11-25 University Of Maryland, Baltimore Novel alanine transaminase enzyme and methods of use
EP1465615B1 (en) 2002-01-15 2012-08-01 Trustees of Dartmouth College Tricyclic-bis-enone derivatives and methods of use thereof
EP1465914B1 (en) 2002-01-18 2008-12-17 Regents Of The University Of Minnesota Triterpene quaternary salts as biologically active surfactants
JP2006515859A (ja) * 2002-05-13 2006-06-08 トラスティーズ オブ ダートマス カレッジ 阻害剤およびその使用法
US20050014730A1 (en) 2003-04-02 2005-01-20 Carlson Robert M. Anti-fungal formulation of triterpene and essential oil
US20050208151A1 (en) 2003-10-30 2005-09-22 Entelos, Inc. Treatment of rheumatoid arthritis with FLIP antagonists
US8288439B2 (en) 2003-11-04 2012-10-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods and compositions for the inhibition of HIV-1 replication
US20060258752A1 (en) 2004-02-12 2006-11-16 Vander Jagt David L Method and compounds for cancer treatment utilizing NFkB as a direct or ultimate target for small molecule inhibitors
JP2005314381A (ja) 2004-03-30 2005-11-10 Anges Mg Inc 増殖性腎疾患の予防・治療・改善剤
JP5087400B2 (ja) 2004-09-07 2012-12-05 パシフィック アロー リミテッド アンゲロイル基を有する抗腫瘍化合物
CA2614110A1 (en) 2005-07-01 2007-01-11 The Johns Hopkins University Compositions and methods for the treatment or prevention of disorders relating to oxidative stress
US20070232577A1 (en) 2006-03-23 2007-10-04 Advanced Life Sciences, Inc. Synthetic pentacyclic triterpenoids and derivatives of betulinic acid and betulin
WO2007127791A2 (en) 2006-04-25 2007-11-08 The Administrators Of The Tulane Educational Fund New pharmacological method for treatment of neuropathic pain
CA2653726C (en) 2006-06-27 2015-05-12 Wellington Laboratories Inc. Glycyrrhetinic acid derivatives
WO2008016095A1 (fr) 2006-08-02 2008-02-07 Santen Pharmaceutical Co., Ltd. REMÈDE PRÉVENTIF OU CURATIF POUR LES KÉRATOCONJONCTIVITES CONTENANT UN ACTIVATEUR DE Nrf2 EN TANT QUE MATIÈRE ACTIVE
JP2008110962A (ja) 2006-08-02 2008-05-15 Santen Pharmaceut Co Ltd Nrf2活性化物質を有効成分として含む角結膜障害の予防または治療剤
WO2008064132A2 (en) 2006-11-17 2008-05-29 Trustees Of Dartmouth College Synthetic triterpenoids and tricyclic-bis-enones for use in stimulating bone and cartilage growth
US7714012B2 (en) 2006-11-17 2010-05-11 Trustees Of Dartmouth University Synthesis and biological activities of new tricyclic-bis-enones (TBEs)
EP2680008A1 (en) 2007-02-08 2014-01-01 Biogen Idec MA Inc. Nrf2 screening assays and related methods and compositions
JP2008247898A (ja) 2007-03-08 2008-10-16 Santen Pharmaceut Co Ltd トリテルペノイドを有効成分として含有する酸化ストレスが関連する眼疾患の予防又は治療剤
US20080254055A1 (en) 2007-04-11 2008-10-16 John Erich Oblong Compositions for Regulation of Hair Growth
WO2008136838A1 (en) 2007-05-04 2008-11-13 Trustees Of Dartmouth College Novel amide derivatives of cddo and methods of use thereof
WO2009023845A2 (en) 2007-08-15 2009-02-19 The Board Of Regents Of The University Of Texas System Combination therapy with synthetic triterpenoids and gemcitabine
US8088824B2 (en) 2007-08-15 2012-01-03 Reata Pharmaceuticals Inc. Forms of CDDO methyl ester
WO2009058849A1 (en) 2007-10-29 2009-05-07 University Of Rochester Use of electrophilic compounds for inducing platelet production or maintaining platelet function
SI2252283T1 (sl) 2008-01-11 2019-02-28 Reata Pharmaceuticals, Inc. Sintetični triterpenoidi in postopki uporabe pri zdravljenju bolezni
EP2271658B1 (en) 2008-04-18 2016-11-09 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: c-17 homologated oleanolic acid derivatives
CN102083442B (zh) 2008-04-18 2014-08-13 里亚塔医药公司 抗氧化剂炎症调节剂:在c-17具有氨基和其它修饰的齐墩果酸衍生物
CN102164941B (zh) * 2008-04-18 2015-05-27 里亚塔医药公司 抗氧化剂炎症调节剂:具有饱和c环的齐墩果酸衍生物
JP5564490B2 (ja) 2008-04-18 2014-07-30 リアタ ファーマシューティカルズ インコーポレイテッド 抗炎症性ファルマコアを含む化合物および使用法
WO2009146216A2 (en) 2008-04-18 2009-12-03 Reata Pharmaceuticals. Inc. Antioxidant inflammation modulators: novel derivatives of oleanolic acid
AU2009274037B2 (en) 2008-07-22 2015-07-09 Trustees Of Dartmouth College Monocyclic cyanoenones and methods of use thereof
US8778990B2 (en) 2008-11-04 2014-07-15 Trustees Of Dartmouth College Betulinic acid derivatives and methods of use thereof
CA2744388A1 (en) 2008-11-21 2010-05-27 The Johns Hopkins University Compositions and methods for treating or preventing radiation injury
SMT201900432T1 (it) 2009-02-13 2019-09-09 Reata Pharmaceuticals Inc Composizioni di dosaggio orali, a rilascio ritardato contenenti cddo-me amorfo
WO2010127029A1 (en) 2009-05-01 2010-11-04 Ophthotech Corporation Methods for treating or preventing ophthalmological diseases
SI2558105T1 (sl) 2010-04-12 2020-02-28 Reata Pharmaceuticals, Inc. Bardoksolon metil za zdravljenje debelosti
WO2011140078A1 (en) 2010-05-04 2011-11-10 Concert Pharmaceuticals, Inc. Synthetic triterpenoid derivatives
US20130288985A1 (en) 2010-07-15 2013-10-31 The Schepens Eye Research Institute Inc. Compositions and methods of treatment of corneal endothelium disorders
CN102070697A (zh) 2010-12-09 2011-05-25 中国药科大学 一种齐墩果酸衍生物、其制备方法及用途
CN102079772A (zh) 2010-12-09 2011-06-01 中国药科大学 一类五环三萜-13,28-内酯化合物、其制备方法和用途
SMT201800069T1 (it) 2010-12-17 2018-03-08 Reata Pharmaceuticals Inc Pirazolil- e pirimidinilenoni triciclici quali modulatori d'infiammazione antiossidanti
PT2670765T (pt) 2011-01-31 2018-01-08 Viiv Healthcare Uk No 4 Ltd Triterpenoides modificados em c-17 e c-3 com atividade inibidora da maturação do vih
CN102153613B (zh) 2011-02-28 2013-08-14 贵州省中国科学院天然产物化学重点实验室 夏枯草酸的制备方法和应用
CN102093462B (zh) 2011-02-28 2012-11-21 贵州省中国科学院天然产物化学重点实验室 1α,2α-二羟基齐墩果酸的制备方法和应用
HUE044081T2 (hu) 2011-03-11 2019-09-30 Reata Pharmaceuticals Inc C4 Monometil-triterpenoid-származékok, és módszerek azok alkalmazására
WO2012154554A1 (en) 2011-05-06 2012-11-15 Catabasis Pharmaceuticals, Inc. Fatty acid triterpene derivatives and their uses
CN102250189B (zh) 2011-05-20 2012-08-29 中国药科大学 一种具有1,12-二烯-3-酮骨架的甘草次酸衍生物、其制备方法及医药用途
SI2841445T1 (sl) 2012-04-27 2017-12-29 Reata Pharmaceuticals, Inc. 2,2-difluoropropionamidni derivati bardoksolon metila, njihove polimorfne oblike in postopki za njihovo uporabo
US8921419B2 (en) 2012-05-08 2014-12-30 Trustees Of Dartmouth College Triterpenoids and compositions containing the same
WO2013169740A2 (en) 2012-05-08 2013-11-14 Trustees Of Dartmouth College Synthetic triterpenoids and methods for modulating stem/progenitor cell gene expression
US8981144B2 (en) 2012-05-08 2015-03-17 Trustees Of Dartmouth College Method for synthesizing 2-cyano-3,12-dioxoolean-1, 9(11)-dien-28-oic acid methyl ester and derivatives thereof
US9556222B2 (en) 2012-06-15 2017-01-31 Reata Pharmaceuticals, Inc. A-ring epoxidized triterpenoid-based anti-inflammation modulators and methods of use thereof
RU2487884C1 (ru) 2012-07-13 2013-07-20 Общество с ограниченной ответственностью "Дакор" (ООО "Дакор") Средство, обладающее антиоксидантной, противовоспалительной, нейропротекторной, гиполипидемической, гипохолестеринемической, гипогликемической, гепатопротекторной, иммуносупрессорной активностями
CN103665087A (zh) 2012-09-03 2014-03-26 上海源力生物技术有限公司 一种萜类化合物及其在医药上的应用
US9278912B2 (en) 2012-09-10 2016-03-08 Reata Pharmaceuticals, Inc. C13-hydroxy derivatives of oleanolic acid and methods of use thereof
JP2015527407A (ja) 2012-09-10 2015-09-17 アッヴィ・インコーポレイテッド グリチルレチン酸誘導体およびその使用方法
EP2892911B1 (en) 2012-09-10 2017-08-30 Reata Pharmaceuticals, Inc. C17-heteroaryl derivatives of oleanolic acid and methods of use thereof
AU2013312106B2 (en) 2012-09-10 2018-03-08 Reata Pharmaceuticals, Inc. C17-alkanediyl and alkenediyl derivatives of oleanolic acid and methods of use thereof
US9512094B2 (en) 2012-09-10 2016-12-06 Reata Pharmaceuticals, Inc. C17-heteroaryl derivatives of oleanolic acid and methods of use thereof
US9656951B2 (en) 2012-09-28 2017-05-23 Applied Pharmaceutical Science, Inc. Polymorphs of CDDO ethyl ester and uses thereof
CN102875634B (zh) 2012-10-24 2014-08-20 苏州晶云药物科技有限公司 2-氰基-3,12-二氧代齐墩果-1,9(11)-二烯-28-酸甲酯的几种晶型
CN102887936A (zh) 2012-10-24 2013-01-23 苏州晶云药物科技有限公司 2-氰基-3,12-二氧代齐墩果-1,9(11)-二烯-28-酸甲酯晶型
TWI649330B (zh) 2013-04-24 2019-02-01 艾伯維有限公司 甲基巴多索龍之2,2-二氟丙醯胺衍生物、其多晶形及其使用方法
TWI716341B (zh) 2013-08-23 2021-01-21 美商瑞塔醫藥有限責任公司 使用齊墩果酸(bardoxolone methyl)或其類似物治療和預防內皮功能障礙之方法
US9464082B2 (en) 2014-01-24 2016-10-11 Abbvie Inc. Aryl and arylalkyl substituted pyrazolyl and pyrimidinyl tricyclic enones as antioxidant inflammation modulators
KR102686868B1 (ko) 2015-02-12 2024-07-19 리아타 파마슈티컬즈, 아이엔씨. 항산화 염증 조절제로서의 이미다졸릴 트리사이클릭 에논
US11584775B2 (en) 2015-09-23 2023-02-21 Reata Pharmaceuticals, Inc. C4-modified oleanolic acid derivatives for inhibition of IL-17 and other uses
US10953020B2 (en) 2016-11-08 2021-03-23 Reata Pharmaceuticals, Inc. Methods of treating Alport syndrome using bardoxolone methyl or analogs thereof
TWI831738B (zh) 2016-12-16 2024-02-11 美商瑞塔醫藥有限責任公司 用於抑制RORγ及其他用途的嘧啶三環烯酮衍生物

Also Published As

Publication number Publication date
CY2024012I1 (el) 2024-12-13
UA116209C2 (uk) 2018-02-26
DOP2014000236A (es) 2015-04-30
CL2014002886A1 (es) 2015-02-06
JP2019011349A (ja) 2019-01-24
JP6637136B2 (ja) 2020-01-29
EA201491972A1 (ru) 2015-02-27
EP3444261A1 (en) 2019-02-20
RS61544B1 (sr) 2021-04-29
WO2013163344A1 (en) 2013-10-31
FIC20240012I1 (fi) 2024-04-18
CA2869783C (en) 2022-06-21
HK1207085A1 (en) 2016-01-22
CY1124130T1 (el) 2022-05-27
US20130324599A1 (en) 2013-12-05
PT2841445T (pt) 2017-09-01
PL2841445T3 (pl) 2017-10-31
CO7170182A2 (es) 2015-01-28
PE20150160A1 (es) 2015-02-19
US11078230B2 (en) 2021-08-03
EA030468B1 (ru) 2018-08-31
HK1207086A1 (en) 2016-01-22
SI2841445T1 (sl) 2017-12-29
LT3444261T (lt) 2021-05-10
SI3444261T1 (sl) 2021-04-30
BR112014026640A2 (pt) 2017-07-18
DK3444261T3 (da) 2021-03-08
US20210355156A1 (en) 2021-11-18
AR092823A1 (es) 2015-05-06
HUE053113T2 (hu) 2021-06-28
PT3444261T (pt) 2021-03-12
US8993640B2 (en) 2015-03-31
TW201726701A (zh) 2017-08-01
US20180009839A1 (en) 2018-01-11
SMT201700396T1 (it) 2017-09-07
CY2024012I2 (el) 2024-12-13
AU2013251602B2 (en) 2017-09-28
JP6410710B2 (ja) 2018-10-24
CY1119333T1 (el) 2018-02-14
TWI623548B (zh) 2018-05-11
US20250051388A1 (en) 2025-02-13
NL301276I2 (nl) 2024-06-24
MX2014013076A (es) 2015-05-11
US9701709B2 (en) 2017-07-11
SMT202100166T1 (it) 2021-05-07
MX357060B (es) 2018-06-25
UY34764A (es) 2013-11-29
EP2841445B1 (en) 2017-06-14
MY172750A (en) 2019-12-11
PL3444261T3 (pl) 2021-07-19
EP2841445A1 (en) 2015-03-04
HUE035673T2 (en) 2018-05-28
KR20150003875A (ko) 2015-01-09
JP2015521166A (ja) 2015-07-27
LT2841445T (lt) 2017-09-11
NZ630222A (en) 2016-06-24
ES2634315T3 (es) 2017-09-27
DK2841445T3 (en) 2017-09-11
US12065464B2 (en) 2024-08-20
HUS2400010I1 (hu) 2024-05-28
SG11201406868XA (en) 2014-11-27
TW201348245A (zh) 2013-12-01
IL235275B (en) 2018-03-29
AU2013251602A1 (en) 2014-10-23
US20150259377A1 (en) 2015-09-17
ES2861393T3 (es) 2021-10-06
RS56154B1 (sr) 2017-11-30
HRP20171275T1 (hr) 2017-10-20
BR112014026640B1 (pt) 2021-05-18
CN104395332B (zh) 2017-01-18
CN104395332A (zh) 2015-03-04
ME02926B (me) 2018-04-20
KR102101774B1 (ko) 2020-04-20
EP3444261B1 (en) 2021-01-13
ZA201407326B (en) 2016-10-26
CA2869783A1 (en) 2013-10-31

Similar Documents

Publication Publication Date Title
FR24C1015I1 (fr) Derives 2,2-difluoropropionamide de bardoxolone methyle, leurs formes polymorphes et leurs procedes d'utilisation
FR22C1047I2 (fr) Derives de benzimidazole-proline
FR17C1040I2 (fr) Derive antiviraux de 2,5-dibenzimidazol-5-yl-1-phenyl-pyrrolidine
EP3356381A4 (en) DESIGN AND SYNTHESIS OF NUCLEOTIDES BASED ON NOVEL DISULFIDE COMPOUNDS AS REVERSIBLE TERMINATORS FOR DNA SEQUENCING BY SYNTHESIS
SMT201600198B (it) Derivati di 1,2,4-triazina-4-ammina
HK1222179A1 (zh) 甲基巴多索隆的 -二氟丙酰胺衍生物、其多晶型形式及使用方法
EP2909214A4 (en) ETP DERIVATIVES
FR22C1023I1 (fr) Forme polymorphe st-246 et procedes de preparation
PL2935303T3 (pl) 4'-fluoronukleozydy, 4'-fluoronukleotydy i ich analogi do leczenia HCV
BR302012003594S1 (pt) "configuração aplicada em fraco"
EP2859439A4 (en) CLOUD APPLICATION DEPLOYMENT
EP2909931A4 (en) CHAIN AMPLIFIER FOR CIRCULAR CURTAIN INTRODUCTION
EP2877461A4 (en) HETEROCYCLIC FLAVOR DERIVATIVES, COMPOSITIONS AND RELATED METHODS
EP2938341A4 (en) Heterocyclic compounds and methods for the use thereof
EP2864479A4 (en) MODULATION OF THE UBE3A ATS EXPRESSION
EP2771022A4 (en) CD40L-SPECIFIC TN3-DERIVED EQUIPMENT AND METHOD FOR THEIR USE
EP2968284A4 (en) ALKYL-AMINE HARMINE DERIVATIVES TO PROMOTE BONE GROWTH
EP2864311A4 (en) SUBSTITUTED TROPOLON DERIVATIVES AND METHODS OF USE
EP2844171A4 (en) OUTPUT OF FASTENERS
FR2973378B1 (fr) Derives d'acide hydroxybisphosphonique bifonctionnels
EP2924033A4 (en) USE OF BENZO FUEL-LOW HEPEROCYCLIC PIPERAZINE OR PIPERIDINE DERIVATIVES FROM NITROGEN
FI20125447L (fi) Fleksografisen päällystysyksikön tarpeenmukainen käyttö
FR2985185B1 (fr) Utilisation en therapeutique de derives d'imidazopyridine
TH1401003816A (th) องค์ประกอบ, การสังเคราะห์, และ วิธีการของการใช้อนุพันธ์ฟีนิลไซโคลอัลคิลเมทธิลเอมีน
FR2990112B1 (fr) Support d'assise